SPEAR TrueDetect™ eMTBR-Tau Assay Kit
The SPEAR TrueDetect™ eMTBR-Tau Assay is the first commercially available singleplex immunoassay for the quantitative measurement of eMTBR-Tau in human plasma. eMTBR-Tau is an emerging Core 2 biomarker associated with neurofibrillary tau tangle pathology in Alzheimer’s disease.
Receive your quote directly from the manufacturer.
Powered by SPEAR’s ultra-sensitive, homogeneous, wash-free immunoassay technology, the assay enables robust measurement using only 1 µL of diluted plasma. Its focused singleplex format and automation-ready workflow make eMTBR-Tau more accessible for translational research, longitudinal studies, and therapeutic development.
Verified for human EDTA plasma. For Research Use Only. Not for use in diagnostic procedures.
Introducing SPEAR epTau 217 and eMTBR-Tau: Dissecting Alzheimer’s pathologies from early Tau phosphorylation to Tau tangles
Wednesday, September 9 at 16:00 BST | 17:00 CEST | 11:00 EDT | 08:00 PDT
The development of reliable blood-based biomarkers is transforming Alzheimer's disease (AD) research, offering new opportunities to detect pathological changes earlier and monitor disease progression with greater precision.
In this SelectScience® webinar, held in partnership with Spear Bio, experts will introduce two novel blood-based biomarker assays designed to advance AD research: SPEAR epTau 217 and SPEAR eMTBR-Tau.
This webinar will present new data on SPEAR epTau 217, which detects a distinct subset of pTau 217 that may represent an early AD-associated Tau species. You will learn how the assay delivers highly consistent results across paired venous and Tasso capillary blood samples and how its performance compares with other Tau biomarkers, including total pTau 217, BD-Tau, and BD-pTau 217.
We will also introduce SPEAR eMTBR-Tau, a plasma biomarker associated with neurofibrillary tangle pathology in late-stage AD. Data will show how plasma eMTBR-Tau levels increase markedly with advancing disease and correlate with neuropathological severity and Tau-PET burden, supporting its potential as a blood-based marker of Tau tangle pathology.
Join us to explore how these assays could enable more accessible, precise, and stage-specific assessment of Alzheimer’s disease pathology.
Certificate of attendance
If you attend the live webinar, you will automatically receive a certificate of attendance, including a learning outcomes summary, for continuing education purposes.
If you view the on-demand webinar, you can request a certificate of attendance by emailing editor@selectscience.net.
Webinar details
- Cost: Free to attend
- Location: Online
- Duration: 60 minutes
Registration is required to secure your place. If you register but can’t attend live, you will receive a link to the on‑demand recording once it becomes available.
